ABVC

ABVC BioPharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing therapeutic solutions in oncology, ophthalmology, and specialized medications. Headquartered in Thousand Oaks, California, the company pursues a diversified strategy that combines proprietary drug development with strategic in-licensing of promising compounds. ABVC's lead oncology candidate, ABV-1701, is a botanical drug derived from Actinidia eriantha for treating non-small cell lung cancer and has completed Phase I clinical trials. The company's ophthalmology program includes ABV-1504, a topical treatment for chronic dry eye disease. Additionally, ABVC markets Vitargus, a dietary supplement containing superoxide dismutase, through its subsidiary Amarillo Biosciences. The company has established manufacturing capabilities and maintains partnerships to advance its product pipeline through clinical development stages. In recent years, ABVC has expanded its portfolio through licensing agreements and acquisitions, including the acquisition of certain assets from ABV Investment Corp. The company trades on the NASDAQ Capital Market under the ticker symbol ABVC. As a development-stage enterprise, ABVC focuses on advancing its clinical programs through regulatory milestones while building commercial infrastructure for potential future product launches. The company collaborates with contract research organizations and manufacturing partners to support its development activities across multiple therapeutic areas.